Sutetinib

DB18841InvestigationalSmall molecule

Sutetinib is under investigation in clinical trial NCT05168566 (Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer).

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₆H₂₅N₅O₂ · 439.519 g/mol (avg)
Also known as: (2e)-n-(3-cyano-7-ethoxy-4-((3-ethynylphenyl)amino)-6-quinolinyl)-4-(dimethylamino)-2-butenamide · 2-butenamide, n-(3-cyano-7-ethoxy-4-((3-ethynylphenyl)amino)-6-quinolinyl)-4-(dimethylamino)-, (2e)-

Resolves to

Compound

UNII538A7S75ABCAS1259519-20-4

Structure

InChIKeyNAVJYTIRRMDRQK-DHZHZOJOSA-NSMILESCCOC1=CC2=NC=C(C#N)C(NC3=CC=CC(=C3)C#C)=C2C=C1NC(=O)\C=C\CN(C)C

Targets

P00533EGFR

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sutetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account